in a paper published in the Lancet, researchers in the UK describe a landmark study in which people with diabetes went into remission—just by losing weight.
Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for OZEMPIC® (semaglutide) injection 0.5 mg or 1 mg, a once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.1 OZEMPIC® is administered once weekly, on the same day each week, and can be taken any time of the day, with or without meals.
Poor nutrition and lack of exercise lead to the increasing prevalence of obesity which, in turn, is the major predictor of diabetes and future risk of cardiovascular disease in western societies. v
New data presented today showed that Jardiance® reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease.
In a new study, a Yale-led research team uncovers how a very low calorie diet can rapidly reverse type 2 diabetes in animal models. If confirmed in people, the insight provides potential new drug targets for treating this common chronic disease, said the researchers.
In a recent study, researchers investigated whether there is a link between children’s antibiotics and the rise of autoimmune diseases such as type 1 diabetes and celiac disease.
Existing digital health products hold the potential to save the nation $46 billion in healthcare spending if they’re deployed comprehensively, according to a new report from IQVIA, which on Tuesday renamed itself from Quintiles/IMS Health.
The World Health Organization (WHO) report that at least 19 million yearly deaths are from cardiometabolic disorders – an umbrella term for cardiovascular disease and conditions such as metabolic syndrome and type 2 diabetes.
One Drop, a leading diabetes care management platform announced they are partnering with Fitbit to help people better manage their Diabetes. By working together, Fitbit and One Drop can help make it easier for people to see how physical activity can impact blood glucose levels and make more informed care management decisions. In addition, One Drop will build an App for Fitbit Ionic, bringing One Drop data to the wrist.
Researchers are one step closer to a new drug that could lower blood glucose levels in patients with insulin resistance, but without the potentially harmful side effects.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.